Lin, Jia-Peng, Huang, Mao-Hua, Sun, Zhi-Ting, Chen, Lei, Lei, Yu-He, Huang, Yu-Qing, Qi, Ming, Fan, Shu-Ran, Chen, Shou-Guo, Chung, Chi-Wing, Chan, Mei-Ching, Liu, Jun-Shan, Hu, Min, Chen, Min-Feng, Ye, Wen-Cai, Chen, Yue-Yue, and Deng, Li-Juan
We aimed to evaluate the effect of periplocin on inhibiting hepatocellular carcinoma (HCC) and further determine its mechanisms. Cytotoxic activity of periplocin against HCC cells was tested by CCK-8 and colony formation assays. The antitumor effects of periplocin were evaluated in human HCC SK-HEP-1 xenograft and murine HCC Hepa 1–6 allograft mouse models. Flow cytometry was used to measure cell cycle distribution, apopotosis, and the number of myeloid-derived suppressor cells (MDSCs). Hoechst 33258 dye was applied to observe the nuclear morphology. Network pharmacology was performed to predict possible signaling pathways. Drug affinity responsive target stability assay (DARTS) was used to evaluate AKT binding of periplocin. Western blotting, immunohistochemistry, and immunofluorescence were used to examine the protein expression levels. Periplocin inhibited cell viability with IC 50 values from 50 nM to 300 nM in human HCC cells. Periplocin disrupted cell cycle distribution and promoted cell apoptosis. Moreover, AKT was predicted as the target of periplocin by network pharmacology, which was confirmed by that AKT/NF-κB signaling was inhibited in periplocin-treated HCC cells. Periplocin also inhibited the expression of CXCL1 and CXCL3 , leading to decreased accumulation of MDSCs in HCC tumors. These findings reveal the function of periplocin in inhibiting HCC progression by G 2 /M arrest, apoptosis and suppression of MDSCs accumulation through blockade of the AKT/NF-κB pathway. Our study further suggests that periplocin has the potential to be developed as an effective therapeutic agent for HCC. [Display omitted] [ABSTRACT FROM AUTHOR]